Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature Reviews Rheumatology

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrrheum.2014.140PMID 25112604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review

  2016cited by this paper
• What does an adult rheumatologist need to know about juvenile idiopathic arthritis?

  2014cited by this paper
• Genome-Wide Data reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases

  2014cited by this paper
• Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

  2013cited by this paper
• Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk Factors

  2013cited by this paper
• 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

  2013cited by this paper
• Metabolomics in the developing infant

  2013cited by this paper
• Risk Markers of Juvenile Idiopathic Arthritis-associated Uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

  2013cited by this paper
• Update on biologicals for treatment of juvenile idiopathic arthritis

  2013cited by this paper
• Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis.

  2013cited by this paper
• The role of metabolomics in neonatal and pediatric laboratory medicine.

  2013cited by this paper
• Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life

  2013cited by this paper
• PharmGKB: the Pharmacogenomics Knowledge Base.

  2013cited by this paper
• Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

  2013cited by this paper
• Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

  2012cited by this paper
• Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease

  2012cited by this paper
• DNA methylome signature in rheumatoid arthritis

  2012cited by this paper
• ABCB1 and ABCC3 Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic Arthritis

  2012cited by this paper
• Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.

  2012cited by this paper
• Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

  2012cited by this paper
• Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis

  2012cited by this paper
• Clinical and epidemiological research

  2011cited by this paper
• Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci

  2011cited by this paper
• A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report

  2011cited by this paper
• Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.

  2011cited by this paper
• Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis

  2011cited by this paper
• 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

  2011cited by this paper
• Molecular Mimicry as a Mechanism of Autoimmune Disease

  2011cited by this paper
• Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions

  2011cited by this paper
• Development of biomarkers to optimize pediatric patient management: what makes children different?

  2011cited by this paper
• PharmGKB summary: methotrexate pathway.

  2011cited by this paper
• American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

  2011cited by this paper
• MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms

  2011cited by this paper
• The epigenetics of autoimmunity

  2011cited by this paper
• Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus

  2011cited by this paper
• The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response.

  2011cited by this paper
• High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score.

  2011cited by this paper
• A Systematic Review and Meta-analysis

  2011cited by this paper
• Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic Arthritis

  2010cited by this paper
• Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

  2010cited by this paper
• Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus.

  2010cited by this paper
• Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype

  2010cited by this paper
• The need for personalised medicine for rheumatoid arthritis

  2010cited by this paper
• Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype

  2010cited by this paper
• Identifying genomic and developmental causes of adverse drug reactions in children.

  2010cited by this paper
• Folate supplementation during methotrexate therapy for rheumatoid arthritis.

  2010cited by this paper
• 677TT Genotype Is Associated with Elevated Risk of Methotrexate (MTX) Toxicity in Juvenile Idiopathic Arthritis: Treatment Outcome, Erythrocyte Concentrations of MTX and Folates, and MTHFR Polymorphisms

  2010cited by this paper
• Demonstrating Utility of Pharmacogenetics in Pediatric Populations: Methodological Considerations

  2010cited by this paper
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• New feature: pathways and important genes from PharmGKB.

  2009cited by this paper
• Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

  2009cited by this paper
• Intronic enhancers coordinate epithelial-specific looping of the active CFTR locus

  2009cited by this paper
• Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

  2009cited by this paper
• Glucose deprivation, oxidative stress and peroxisome proliferator-activated receptor-alpha (PPARA) cause peroxisome proliferation in preimplantation mouse embryos.

  2009cited by this paper
• The ontogeny of drug metabolism enzymes and implications for adverse drug events.

  2008cited by this paper
• Pediatric Rheumatology for the Adult Rheumatologist

  2008cited by this paper
• Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis

  2008cited by this paper
• Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

  2008cited by this paper
• Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.

  2008cited by this paper
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

  2008cited by this paper
• Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

  2008cited by this paper
• Measuring clinical response and remission in juvenile idiopathic arthritis

  2007cited by this paper
• DNA Methylation and Systemic Lupus Erythematosus

  2007cited by this paper
• Genome scan implicates adhesion biological pathways in secondary leukemia

  2007cited by this paper
• Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice

  2007cited by this paper
• Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside

  2007cited by this paper
• 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.

  2007cited by this paper
• Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy

  2007cited by this paper
• Clinical pharmacogenetics in pediatric patients.

  2007cited by this paper
• The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice.

  2007cited by this paper
• IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors

  2007cited by this paper
• Future of Pediatric Therapeutics: Reauthorization of BPCA and PREA

  2007cited by this paper
• Juvenile idiopathic arthritis.

  2007cited by this paper
• Adenosine in inflammatory joint diseases

  2007cited by this paper
• Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.

  2007cited by this paper
• Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis

  2007cited by this paper
• Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.

  2007cited by this paper
• Future of Pediatric Therapeutics: Reauthorization of BPCA and PREA

  2007cited by this paper
• Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis

  2006cited by this paper
• Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.

  2006cited by this paper
• Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis.

  2006cited by this paper
• Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.

  2006cited by this paper
• Non‐estrogen treatments for osteoporosis An evidence‐based review

  2006cited by this paper
• The Novel PIAS-like Protein hZimp10 Enhances Smad Transcriptional Activity*

  2006cited by this paper
• Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.

  2006cited by this paper
• Update on the medical treatment of juvenile idiopathic arthritis

  2006cited by this paper
• Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.

  2005cited by this paper
• Outcome following onset of juvenile idiopathic inflammatory arthritis: I. frequency of different outcomes.

  2005cited by this paper
• Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis

  2005cited by this paper
• The pharmacogenetics of methotrexate in inflammatory bowel disease.

  2005cited by this paper
• Methodological Considerations

  2005cited by this paper
• Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters.

  2005cited by this paper
• Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.

  2005cited by this paper
• Patterns of clinical remission in select categories of juvenile idiopathic arthritis.

  2005cited by this paper
• [Treatment of juvenile idiopathic arthritis].

  2005cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• Part II

  2004cited by this paper
• The New Paradigm

  2004cited by this paper

• Glutathione S-Transferase Gene Polymorphisms as Predictors of Methotrexate Efficacy in Juvenile Idiopathic Arthritis

  2024cites this paper
• An Update on the Genetics of IgA Nephropathy

  2023cites this paper
• Genetic Variants and Therapeutic Response to Anti–TNF-α Agents in Juvenile Idiopathic Arthritis

  2022cites this paper
• Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model

  2021cites this paper
• Current and emerging biologics for the treatment of juvenile idiopathic arthritis

  2020cites this paper
• The relationship of the immune response mediator genes’ polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis

  2020cites this paper
• Contemporary Management of Temporomandibular Disorders: Non-Surgical Treatment

  2019cites this paper
• Medical Management of TMD

  2019cites this paper
• Association of MTHF 677TT with adverse drug reactions and RFC G80A with non-response and adverse drug reactions in methotrexate therapy

  2018cites this paper
• Recent advances in our understanding of the pathogenesis of juvenile idiopathic arthritis and their potential clinical implications

  2018cites this paper
• Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting

  2018cites this paper
• In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine?

  2017cites this paper
• CD3+CD56+ natural killer T cell activity in children with different forms of juvenile idiopathic arthritis and the influence of etanercept treatment on polyarticular subgroup.

  2017cites this paper
• Precision medicine in pediatric rheumatology

  2017cites this paper
• Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters

  2017cites this paper
• Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis

  2017cites this paper
• Are we closer to personalized therapy in juvenile idiopathic arthritis?

  2016cites this paper
• The role of CD73 in the pathogenesis of Juvenile Idiopathic Arthritis

  2015cites this paper
• Impact of ABCB1 Single-Nucleotide Polymorphisms on Treatment Outcomes with Salmeterol/Fluticasone Combination Therapy for Stable Chronic Obstructive Pulmonary Disease

  2015cites this paper
• Genetic determinants for methotrexate response in juvenile idiopathic arthritis

  2015influential citation